Research ExplorerPublicationsCan Routine Imaging After Neoadjuvant Chemotherapy in Breast...

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

Standard

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? / Schaefgen, B; Mati, M; Sinn, H P; Golatta, M; Stieber, A; Rauch, G; Hennigs, A; Richter, H; Domschke, C; Schuetz, F; Sohn, C; Schneeweiss, A; Heil, Joerg.

In: ANN SURG ONCOL, Vol. 23, No. 3, 03.2016, p. 789-795.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schaefgen, B, Mati, M, Sinn, HP, Golatta, M, Stieber, A, Rauch, G, Hennigs, A, Richter, H, Domschke, C, Schuetz, F, Sohn, C, Schneeweiss, A & Heil, J 2016, 'Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?', ANN SURG ONCOL, vol. 23, no. 3, pp. 789-795. https://doi.org/10.1245/s10434-015-4918-0

APA

Schaefgen, B., Mati, M., Sinn, H. P., Golatta, M., Stieber, A., Rauch, G., Hennigs, A., Richter, H., Domschke, C., Schuetz, F., Sohn, C., Schneeweiss, A., & Heil, J. (2016). Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? ANN SURG ONCOL, 23(3), 789-795. https://doi.org/10.1245/s10434-015-4918-0

Vancouver

Schaefgen B, Mati M, Sinn HP, Golatta M, Stieber A, Rauch G et al. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? ANN SURG ONCOL. 2016 Mar;23(3):789-795. https://doi.org/10.1245/s10434-015-4918-0

Bibtex

@article{66b6ea6a59eb466a86badc181843d3e5,
title = "Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?",
abstract = "BACKGROUND: This study evaluated breast imaging procedures for predicting pathologic complete response (pCR = ypT0) after neoadjuvant chemotherapy (NACT) for breast cancer to challenge surgery as a diagnostic procedure after NACT.METHODS: This retrospective, exploratory, monocenter study included 150 invasive breast cancers treated by NACT. The patients received magnetic resonance imaging (MRI), mammography (MGR), and ultrasound (US). The results were classified in three response subgroups according to response evaluation criteria in solid tumors. To incorporate specific features of MRI and MGR, an additional category [clinical near complete response (near-cCR)] was defined. Residual cancer in imaging and pathology was defined as a positive result. Negative predictive values (NPVs), false-negative rates (FNRs), and false-positive rates (FPRs) of all imaging procedures were analyzed for the whole cohort and for triple-negative (TN), HER2-positive (HER2+), and HER2-negative/hormone-receptor-positive (HER2-/HR+) cancers, respectively.RESULTS: In 46 cases (31%), pCR (ypT0) was achieved. Clinical complete response (cCR) and near-cCR showed nearly the same NPVs and FNRs. The NPV was highest with 61% for near-cCR in MRI and lowest with 44% for near-cCR in MGR for the whole cohort. The FNRs ranged from 4 to 25% according to different imaging methods. The MRI performance seemed to be superior, especially in TN cancers (NPV 94%; FNR 5%). The lowest FPR was 10 % in MRI, and the highest FPR was 44% in US.CONCLUSION: Neither MRI nor MGR or US can diagnose a pCR (ypT0) with sufficient accuracy to replace pathologic diagnosis of the surgical excision specimen.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Chemotherapy, Adjuvant, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Middle Aged, Multimodal Imaging, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Retrospective Studies, Triple Negative Breast Neoplasms, Journal Article",
author = "B Schaefgen and M Mati and Sinn, {H P} and M Golatta and A Stieber and G Rauch and A Hennigs and H Richter and C Domschke and F Schuetz and C Sohn and A Schneeweiss and Joerg Heil",
year = "2016",
month = mar,
doi = "10.1245/s10434-015-4918-0",
language = "English",
volume = "23",
pages = "789--795",
journal = "ANN SURG ONCOL",
issn = "1068-9265",
publisher = "Springer New York",
number = "3",

}

RIS

TY - JOUR

T1 - Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

AU - Schaefgen, B

AU - Mati, M

AU - Sinn, H P

AU - Golatta, M

AU - Stieber, A

AU - Rauch, G

AU - Hennigs, A

AU - Richter, H

AU - Domschke, C

AU - Schuetz, F

AU - Sohn, C

AU - Schneeweiss, A

AU - Heil, Joerg

PY - 2016/3

Y1 - 2016/3

N2 - BACKGROUND: This study evaluated breast imaging procedures for predicting pathologic complete response (pCR = ypT0) after neoadjuvant chemotherapy (NACT) for breast cancer to challenge surgery as a diagnostic procedure after NACT.METHODS: This retrospective, exploratory, monocenter study included 150 invasive breast cancers treated by NACT. The patients received magnetic resonance imaging (MRI), mammography (MGR), and ultrasound (US). The results were classified in three response subgroups according to response evaluation criteria in solid tumors. To incorporate specific features of MRI and MGR, an additional category [clinical near complete response (near-cCR)] was defined. Residual cancer in imaging and pathology was defined as a positive result. Negative predictive values (NPVs), false-negative rates (FNRs), and false-positive rates (FPRs) of all imaging procedures were analyzed for the whole cohort and for triple-negative (TN), HER2-positive (HER2+), and HER2-negative/hormone-receptor-positive (HER2-/HR+) cancers, respectively.RESULTS: In 46 cases (31%), pCR (ypT0) was achieved. Clinical complete response (cCR) and near-cCR showed nearly the same NPVs and FNRs. The NPV was highest with 61% for near-cCR in MRI and lowest with 44% for near-cCR in MGR for the whole cohort. The FNRs ranged from 4 to 25% according to different imaging methods. The MRI performance seemed to be superior, especially in TN cancers (NPV 94%; FNR 5%). The lowest FPR was 10 % in MRI, and the highest FPR was 44% in US.CONCLUSION: Neither MRI nor MGR or US can diagnose a pCR (ypT0) with sufficient accuracy to replace pathologic diagnosis of the surgical excision specimen.

AB - BACKGROUND: This study evaluated breast imaging procedures for predicting pathologic complete response (pCR = ypT0) after neoadjuvant chemotherapy (NACT) for breast cancer to challenge surgery as a diagnostic procedure after NACT.METHODS: This retrospective, exploratory, monocenter study included 150 invasive breast cancers treated by NACT. The patients received magnetic resonance imaging (MRI), mammography (MGR), and ultrasound (US). The results were classified in three response subgroups according to response evaluation criteria in solid tumors. To incorporate specific features of MRI and MGR, an additional category [clinical near complete response (near-cCR)] was defined. Residual cancer in imaging and pathology was defined as a positive result. Negative predictive values (NPVs), false-negative rates (FNRs), and false-positive rates (FPRs) of all imaging procedures were analyzed for the whole cohort and for triple-negative (TN), HER2-positive (HER2+), and HER2-negative/hormone-receptor-positive (HER2-/HR+) cancers, respectively.RESULTS: In 46 cases (31%), pCR (ypT0) was achieved. Clinical complete response (cCR) and near-cCR showed nearly the same NPVs and FNRs. The NPV was highest with 61% for near-cCR in MRI and lowest with 44% for near-cCR in MGR for the whole cohort. The FNRs ranged from 4 to 25% according to different imaging methods. The MRI performance seemed to be superior, especially in TN cancers (NPV 94%; FNR 5%). The lowest FPR was 10 % in MRI, and the highest FPR was 44% in US.CONCLUSION: Neither MRI nor MGR or US can diagnose a pCR (ypT0) with sufficient accuracy to replace pathologic diagnosis of the surgical excision specimen.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Chemotherapy, Adjuvant

KW - Diagnostic Imaging

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoenzyme Techniques

KW - Middle Aged

KW - Multimodal Imaging

KW - Neoadjuvant Therapy

KW - Neoplasm Grading

KW - Neoplasm Invasiveness

KW - Neoplasm Staging

KW - Prognosis

KW - Receptor, ErbB-2

KW - Receptors, Estrogen

KW - Receptors, Progesterone

KW - Retrospective Studies

KW - Triple Negative Breast Neoplasms

KW - Journal Article

U2 - 10.1245/s10434-015-4918-0

DO - 10.1245/s10434-015-4918-0

M3 - SCORING: Journal article

C2 - 26467456

VL - 23

SP - 789

EP - 795

JO - ANN SURG ONCOL

JF - ANN SURG ONCOL

SN - 1068-9265

IS - 3

ER -